Mesoblast's ryoncil® is the first u.s. fda-approved mesenchymal stromal cell (msc) therapy

New york, dec. 18, 2024 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the food and drug administration (fda) approved ryoncil® (remestemcel-l) as the first mesenchymal stromal cell (msc) therapy in the united states. ryoncil is the only msc therapy approved in the u.s. for any indication, and the only approved therapy for steroid-refractory acute graft versus host disease (sr-agvhd) in children 2 months and older, including adolescents and teenagers.
MESO Ratings Summary
MESO Quant Ranking